ALT1 Stock Chart & Stats
$48.50
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$40.00 - $111.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.86K
Market Cap
$9.42B
Enterprise Value$87.61
Total Cash (Recent Filing)$331.54M
Total Debt (Recent Filing)$35.85M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Aug 06, 2026EPS Estimate
-2.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding194,474,150
10 Day Avg. Volume1,121
30 Day Avg. Volume2,863
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$267.01Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-10.84
Revenue Forecast (FY)$108.94K
ALT1 FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was $40.00 and its highest was $111.00 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is $9.42B.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Aug 06, 2026 which is in 11 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on May 13, 2026. The company reported -$3.152 earnings per share for the quarter, beating the consensus estimate of -$4.237 by $1.086.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune does not currently pay dividends.
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -2.45.
How many shares outstanding does Altimmune have?
Altimmune has 194,474,150 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -$3.152 in its last earnings report, beating expectations of -$4.237. Following the earnings report the stock price went down -2.49%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in MX:ALT1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$267.01 (― Downside)
$267.01 (― Downside)
Blogger Sentiment
Bullish
MX:ALT1 Sentiment 70%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
113.42%
Trailing 12-Months
Company Description
Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
ALT1 Stock 12 Month Forecast
Average Price Target
$267.01